Germany· DE-A57-16e5a33ac79edbd0
Pazopanib Bluepharma
A pazopanib product containing pazopanib, registered in Germany by Bluepharma Indústria Farmacêutica S.A.. The same ATC class is registered in 14 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Pazopanib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EX03 (pazopanib), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 8 of them publish a price we can compare per daily dose
Pazopanib · ATC L01EX03
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of pazopanib costs, country by country.
Normalised to the WHO defined daily dose (0.8 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Pazopanib · price per daily dose (0.8 g)
USD · FX 28 Sept 2026
- CH Switzerland$87.69
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Pazopanib
- Manufacturer
- Bluepharma Indústria Farmacêutica S.A.
- Country
- Germany (DE)
- ATC code
- L01EX03
- ATC class
- Pazopanib
- Defined daily dose
- 0.8 g, O
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
593 interactions on record for pazopanib.
Graded by severity as the source publishes them — 155 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pazopanib · interactions on record
593 records
- 155 severe
- 428 moderate
- 10 minor
Most severe, free to view
- CimetidineA02BA01severe
- RanitidineA02BA02severe
- FamotidineA02BA03severe
- NizatidineA02BA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pazopanib in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaPAZOPANIB ACCORDACCORD HEALTHCARE POLSKA Sp. z o.o., Varšava
- PolandPazopanib AccordAccord Healthcare Polska Sp. z o.o.
- NetherlandsPazopanib Accord 200 mg filmomhulde tablettenAccord Healthcare B.V.
- FinlandPazopanib AccordAccord Healthcare B.V.
- FrancePAZOPANIB ACCORD 200 mg, comprimé pelliculéACCORD HEALTHCARE FRANCE
- SwedenPazopanib Accord 200 mg Filmdragerad tablettAccord Healthcare B.V.
- United StatespazopanibNovugen Pharma (USA) LLC.
- SpainPAZOPANIB ACCORD 200 MG COMPRIMIDOS RECUBIERTOS CON PELÍCULA EFGAccord Healthcare S.L.U.
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Pazopanib Devatis
- Belgium · Pazopanib Accord, Pazopanib Eg
- Bulgaria · Алуниб, Пазопаниб G.L. Pharma
- Cyprus · Pazopanib Sapiens, Pazorem
- Czechia · Pazopanib Accord, Pazopanib Sandoz
- Denmark · Pazopanib Accord, Pazopanib Glenmark
- Estonia · Pazopanib Accord, Pazopanib Teva
- Spain · Pazopanib Accord, Pazopanib Dr. Reddys
- Finland · Pazopanib Accord, Pazopanib Glenmark
- France · Pazopanib Accord, Pazopanib Biogaran
- United Kingdom (Northern Ireland) · Pazopanib Accord, Pazopanib Accord Healthcare
- Greece · Pazopanib Accord, Pazopanib Stada
- Croatia · Pazopanib Accord, Pazopanib Frontier
- Hungary · Pazopanib Accord, Pazopanib G.L. Pharma
- Ireland · Pazopanib Accord, Pazopanib Reddy
- Iceland · Pazopanib Adalvo, Pazopanib Stada
- Italy · Pazopanib Accord, Pazopanib Dr. Reddy’s
- Liechtenstein · Votrient
- Lithuania · Pazopanib Accord, Pazopanib Auxilia
- Luxembourg · Pazopanib Eg, Pazopanib Pazopanib Eg
- Latvia · Pazopanib Accord, Pazopanib Teva
- Malta · Pazopanib Pharmacare, Pazopanib Pharos
- Netherlands · Pazopanib Accord, Pazopanib Cf
- Norway · Pazopanib Accord, Pazopanib Glenmark
- Poland · Pazopanib Accord, Pazopanib Glenmark
- Portugal · Pazopanib Accord, Pazopanib Bluepharma
- Romania · Pazopanib Accord, Pazopanib Dr. Reddys
- Sweden · Pazopanib Accord, Pazopanib Glenmark
- Slovenia · Pazopanib Accord, Pazopanib Teva
- Slovakia · Pazopanib Accord, Pazopanib G.L. Pharma
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bb0ce655-4764-4f00-a332-f3fbe9f2ba02 GET /v1/drugs/bb0ce655-4764-4f00-a332-f3fbe9f2ba02?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Oral Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Pazopanib",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about pazopanib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.